{"entity":{"id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of Gedatolisib, Darolutamide in prostate cancer, run by Celcuity Inc, now recruiting.","summary":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06190899 by Celcuity Inc, with 54 participants planned, started 2024-01-01 and due to reach its primary completion in 2028-01. Interventions recorded: Gedatolisib, Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06190899","url":"https://clinicaltrials.gov/study/NCT06190899"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["androgen-deprivation","kinase-inhibitors"],"targets":[],"drugs":["gedatolisib","darolutamide"],"companies":["celcuity"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06190899","phase":"1/2","setting":"A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Celcuity Inc","started":"2024-01-01","startedType":"actual","enrolled":54,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06190899/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/"}],"company":[{"id":"celcuity","kind":"company","name":"Celcuity","route":"/companies/celcuity/"}]}}